Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HY-PAM "25" vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydroxyzine pamoate is a piperazine antihistamine that acts as a histamine H1-receptor antagonist, thereby suppressing histamine-mediated responses in the skin and mucous membranes. Additionally, it exhibits anxiolytic and sedative properties through central nervous system depression via inhibition of subcortical regions.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Symptomatic relief of anxiety and tension associated with psychoneurosis,Adjunct in organic disease states with anxiety,Pruritus due to allergic conditions such as chronic urticaria, atopic and contact dermatoses
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
25 mg orally once daily, preferably at bedtime, for short-term treatment of insomnia.
250 mg orally twice daily
Terminal elimination half-life 6-8 hours in healthy adults; prolonged to 12-18 hours in renal impairment (Cr Cl <30 m L/min) and in elderly patients.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Primarily hepatic via CYP3A4 and CYP2D6 isoenzymes; major metabolite is cetirizine.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Primarily renal (60-70% unchanged drug), with 30-40% biliary/fecal elimination as metabolites.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
95-98% bound to albumin and alpha-1-acid glycoprotein.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
0.2-0.3 L/kg, indicating primarily plasma and extracellular fluid distribution.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: 60-70% (due to first-pass metabolism); Rectal: 80-90%; Intramuscular: 100%.
70-90% (oral); 100% (IV).
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), use with caution; no specific dose recommendation available.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
For Child-Pugh Class A or B, dose reduction to 12.5 mg daily may be considered due to increased exposure; avoid use in Child-Pugh Class C (severe hepatic impairment).
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not established; contraindicated in pediatric patients due to lack of safety and efficacy data.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Start at 12.5 mg daily; maximum dose 25 mg daily due to increased sensitivity and risk of falls, cognitive impairment, and adverse effects.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
May cause QT prolongation, especially in patients with risk factors,Use with caution in patients with narrow-angle glaucoma, prostatic hypertrophy, or urinary retention,Central nervous system depressant effects may impair mental or physical abilities,Avoid concurrent use with alcohol or other CNS depressants,Use with caution in elderly patients due to increased sensitivity and anticholinergic effects
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypersensitivity to hydroxyzine or any component,Early pregnancy (first trimester) due to potential fetal harm,Porphyria (may precipitate attacks),Concomitant use with monoamine oxidase inhibitors
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
No significant food interactions known.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
HY-PAM 25 is a benzodiazepine. First trimester: Data suggest an increased risk of oral clefts (approximately 0.6% vs 0.4% background). Second trimester: Possible risk of other malformations, but data are limited. Third trimester: Chronic use may cause neonatal withdrawal, floppy infant syndrome (hypotonia, lethargy, feeding difficulties), and respiratory depression at delivery.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Benzodiazepines like HY-PAM 25 are excreted in breast milk. The M/P ratio is approximately 0.5-0.7. With short-acting agents and moderate doses, risk to infant is low but monitor for sedation and poor feeding. Avoid breastfeeding if high maternal doses or chronic use; consider alternative agent.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
Increased clearance and volume of distribution in pregnancy may require dose adjustment. For HY-PAM 25, consider increasing the dose by 20-30% in third trimester to maintain efficacy, but taper postpartum to avoid accumulation. Use lowest effective dose and avoid chronic use.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
HY-PAM '25' is a compounded topical formulation containing hydrocortisone 2.5%, pramoxine 1%, and aluminum acetate 0.25%. Use for acute inflammatory dermatoses with pruritus and exudation. Avoid prolonged use on intertriginous areas. Discontinue if signs of skin atrophy or secondary infection develop.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Apply a thin layer to affected areas 3-4 times daily.,Do not use on broken skin, deep wounds, or infected skin without medical guidance.,Avoid contact with eyes and mucous membranes.,Do not cover with bandages or dressings unless directed by your doctor.,Report any worsening of rash, burning, or signs of skin thinning.,Do not use for more than 2 weeks unless directed by your doctor.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HY-PAM "25" vs ALDOCLOR-250, answered by our medical review team.
HY-PAM "25" is a Antihypertensive Combination that works by Hydroxyzine pamoate is a piperazine antihistamine that acts as a histamine H1-receptor antagonist, thereby suppressing histamine-mediated responses in the skin and mucous membranes. Additionally, it exhibits anxiolytic and sedative properties through central nervous system depression via inhibition of subcortical regions.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HY-PAM "25" and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HY-PAM "25" is: 25 mg orally once daily, preferably at bedtime, for short-term treatment of insomnia.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HY-PAM "25" and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HY-PAM "25" is classified as Category C. HY-PAM 25 is a benzodiazepine. First trimester: Data suggest an increased risk of oral clefts (approximately 0.6% vs 0.4% background). Second trimester: Possible risk of other malf. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.